See more : RealNetworks, Inc. (RNWK) Income Statement Analysis – Financial Results
Complete financial analysis of Evaxion Biotech A/S (EVAX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evaxion Biotech A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hiroshima Electric Railway Co.,Ltd. (9033.T) Income Statement Analysis – Financial Results
- Perrigo Company plc (PRGO) Income Statement Analysis – Financial Results
- Koninklijke KPN N.V. (KKPNF) Income Statement Analysis – Financial Results
- Bodycote plc (BYPLF) Income Statement Analysis – Financial Results
- Cabio Biotech (Wuhan) Co., Ltd. (688089.SS) Income Statement Analysis – Financial Results
Evaxion Biotech A/S (EVAX)
About Evaxion Biotech A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 73.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 112.00 | 571.32K | 343.45K | 105.72K | 80.98K | 73.93K |
| Gross Profit | 72.89K | -571.32K | -343.45K | -105.72K | -80.98K | -73.93K |
| Gross Profit Ratio | 99.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.92M | 17.06M | 19.58M | 10.90M | 8.22M | 3.73M |
| General & Administrative | 10.35M | 8.21M | 6.25M | 5.67M | 2.63M | 1.88M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.35M | 8.21M | 6.25M | 5.67M | 2.63M | 1.88M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 16.00K | 15.00K |
| Operating Expenses | 22.25M | 25.26M | 25.83M | 16.57M | 10.86M | 5.63M |
| Cost & Expenses | 22.27M | 25.26M | 25.83M | 16.57M | 10.86M | 5.63M |
| Interest Income | 154.00K | 2.83M | 2.04M | 216.00K | 9.00K | 2.00K |
| Interest Expense | 897.00K | 1.51M | 915.00K | 223.00K | 1.22M | 698.00K |
| Depreciation & Amortization | 615.95K | 571.32K | 343.45K | 105.72K | 80.98K | 73.93K |
| EBITDA | -21.40M | -22.58M | -24.17M | -16.46M | -11.90M | -6.18M |
| EBITDA Ratio | -29,319.18% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.20M | -25.26M | -25.83M | -16.57M | -10.86M | -5.63M |
| Operating Income Ratio | -30,406.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -718.00K | 1.32M | 1.12M | -7.00K | -1.16M | -636.93K |
| Income Before Tax | -22.92M | -23.94M | -24.71M | -16.58M | -12.02M | -6.27M |
| Income Before Tax Ratio | -31,390.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -791.22K | -772.00K | -178.00K | -1.56M | -825.00K | -735.00K |
| Net Income | -22.13M | -23.17M | -24.53M | -15.02M | -11.20M | -5.54M |
| Net Income Ratio | -30,308.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -8.11 | -9.80 | -12.58 | -9.27 | -6.91 | -2.88 |
| EPS Diluted | -8.11 | -9.80 | -12.58 | -9.27 | -6.91 | -2.88 |
| Weighted Avg Shares Out | 2.73M | 2.36M | 1.95M | 1.62M | 1.62M | 1.92M |
| Weighted Avg Shares Out (Dil) | 2.73M | 2.36M | 1.95M | 1.62M | 1.62M | 1.92M |
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
COPENHAGEN, Denmark, April 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces that the first patient in its EVX-01 Phase 2 trial in metastatic...
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.
Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript
Evaxion Biotech A/S (EVAX) Q4 2023 Results Conference Call April 2, 2024 9:00 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rono - Chief Scientific Officer Jesper Nissen - Chief Operating Officer and Chief Financial Officer Conference...
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
COPENHAGEN, Denmark, April 02, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is pleased to announce the successful conclusion of a series of large non-rodent...
EVAX Stock Earnings: Evaxion Biotech Meets EPS for Q4 2023
Evaxion Biotech (NASDAQ: EVAX ) just reported results for the fourth quarter of 2023. Evaxion Biotech reported earnings per share of -$1.60.
Evaxion Announces Business Update and Full Year 2023 Financial Results
COPENHAGEN, Denmark, March 27, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today provides a business update and announces full year 2023 financial results.
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
COPENHAGEN, Denmark, March 19, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today hosts a Research & Development (R&D) Day focusing on its core AI-Immunology™...
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announces that it will host a Research & Development (R&D) Day focusing...
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with...
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on February 05, 2024, it received a Notification Letter from...
Source: https://incomestatements.info
Category: Stock Reports